AZR · Azora Therapeutics, Inc. (DE) · Documents

Oct 2

Proxy statement DEF 14A Meeting Nov 2, 2023

Proxy statement

Oct 2

Annual report to holders ARS

Annual report to holders

Sep 27

Current report 8-K Events of Sep 26

Other events

Sep 21

Current report 8-K Events of Sep 18

Entered into a material agreement, Director or officer change, or executive pay

Sep 11

Current report 8-K

Regulation FD disclosure

Aug 23

Current report 8-K Events of Aug 21

Delisting notice or listing transfer

Aug 21

Current report 8-K

Financial results

Aug 21

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net income $1.09M Diluted EPS $0.96

Aug 18

Current report 8-K Events of Jun 30

Completed an acquisition or sale of assets

Aug 15

Late filing notice NT 10-Q

Late filing notice

Aug 4

Current report 8-K Events of Aug 3

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events

Jul 13

Registration statement S-1/A

Registration statement

Jul 10

Current report 8-K Events of Jul 7

Delisting notice or listing transfer

Jun 23

Registration statement S-1

Registration statement

Jun 9

Current report 8-K

Regulation FD disclosure

Jun 2

Current report 8-K Events of May 31

Entered into a material agreement, Unregistered sale of equity

May 24

Current report 8-K Events of May 19

Delisting notice or listing transfer

May 12

Current report 8-K

Financial results

May 12

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $2.91M Diluted EPS -$0.11

May 10

Current report 8-K Events of May 8

Entered into a material agreement, Regulation FD disclosure

Apr 13

Current report 8-K Events of Apr 12

Shareholder vote results

Mar 31

Current report 8-K Events of Mar 30

Financial results

Mar 30

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $12.73M Diluted EPS -$0.51

Mar 29

Proxy statement DEFA14A

Proxy statement

Mar 21

Current report 8-K Events of Mar 15

Entered into a material agreement, Regulation FD disclosure

Mar 7

Current report 8-K Events of Mar 6

Regulation FD disclosure, Other events

Mar 6

Proxy statement DEF 14A Meeting Apr 12, 2023

Proxy statement

Mar 2

Current report 8-K Events of Feb 28

Delisting notice or listing transfer

Feb 27

Current report 8-K Events of Feb 24

Other events

Feb 24

Current report 8-K Events of Feb 23

Entered into a material agreement, Unregistered sale of equity, Other events

Feb 24

Proxy statement PRE 14A

Proxy statement

Feb 21

Current report 8-K

Regulation FD disclosure, Other events

Feb 1

Current report 8-K Events of Jan 27

Entered into a material agreement, Regulation FD disclosure

Nov 15

Current report 8-K Events of Nov 14

Financial results

Nov 14

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $3.11M Diluted EPS -$0.12

Oct 13

Current report 8-K

Director or officer change, or executive pay, Shareholder vote results

Sep 26

Current report 8-K

Regulation FD disclosure, Other events

Sep 14

Current report 8-K Events of Sep 13

Change of auditor

Sep 13

Current report 8-K Events of Sep 8

Director or officer change, or executive pay

Sep 6

Current report 8-K

Regulation FD disclosure, Other events

Sep 2

Current report 8-K Events of Aug 31

Delisting notice or listing transfer

Sep 1

Proxy statement DEF 14A Meeting Oct 13, 2022

Proxy statement

Aug 23

Current report 8-K Events of Aug 18

Director or officer change, or executive pay

Aug 16

Current report 8-K

Financial results

Aug 15

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $3.85M Diluted EPS -$0.16

Jul 20

Current report 8-K

Regulation FD disclosure, Other events

Jun 27

Current report 8-K

Regulation FD disclosure, Other events

May 16

Current report 8-K

Financial results

May 16

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Net loss $2.91M

Apr 6

Registration statement S-3/A

Registration statement